BIND Therapeutics (BIND) and Pfizer (PFE) Accurins Deal Timeline
Post# of 190
Posted On: 04/05/2015 7:55:37 PM
Crown Equity Holdings Inc. (CRWE) is currently developing its CRWE Network ( www.CRWE-PR.com ), a growing network of community targeted sites.
CRWE Network's business model is based on selling advertising to businesses targeting both locally and nationally
The CRWE Network has reached the 1487th community website in the U.S. and includes coverage in the states of California, Mississippi, Michigan, Florida, Nevada and New York, as well as across 10 provinces in Canada.
The CRWE-PR Business Directory portal ( www.BusinessDirectory.crwe-pr.com ) is the company’s business directory service that is available to all United States and Canada business in the public and private sector. It allows business owners and executives the ability to claim their business listings and provide more detailed information for their potential customers who visit the CRWE Network everyday.
The CRWE-PR Finance website ( www.finance.crwe-pr.com ) allows Crown Equity Holdings the instant distribution of breaking business and financial news to the entire CRWE Network
The company’s CRWE Press Release ( www.crwepressrelease.com ) offers increased visibility with cost effective solutions through the distribution of information to the entire CRWE Network for both public and private companies.
Crown Equity Holdings’ CRWE Real Estate ( www.CRWERealEstate.com ) is expected to be integrated in all the CRWE Network. It will allow people to submit their listings for exposure to visitors searching for homes.
Online video is gaining strength as a source for content marketing. Strategic plans are being developed for the company’s division CRWE Tube ( www.crwetube.com ), expected to be integrated in all the CRWE Network
The Medical Marijuana CRWE-PR website ( www.medicalmarijuana.crwe-pr.com ) is a news and information database of medical marijuana doctors, dispensaries, deliveries and lawyers across the nation.
CRWE‘s subsidiary EQCO2, Inc. (CLNO) is in the process of changing its name for iB2B Global and its direction of operations to that of a business to business (B2B) international e-commerce company with an online and mobile optimized platform to facilitate e-commerce between manufacturers and buyers.
CRWE‘s iB2B Global ( www.iB2BGlobal.com ) was created to bring business communities from similar and different continents together online, enabling a cost effective access point for bulk products to be bought, sold and shipped in a timely manner.
CRWE has signed a Letter of Intent (LOI) to acquire 95% stake in American Video Teleconferencing Corp. (AVOT), which has two (2) sub-company operations known as, Roxzu and AVOTube.
Roxzu ( www.roxzu.com ) in development stage, is an on-line e-commerce coupon distribution channel and marketplace for merchants to create brand awareness for their business. The geo-location based mobile marketing application Roxzu is expected to be integrated in all the CRWE Network.
AVOTube ( www.avotube.com ) is a video-sharing hosting service that allows user to upload videos to share for exposure, branding, marketing and advertising.
CRWE provides marketing solutions that boost customer awareness and merchant visibility on the Internet.
More about Crown Equity Holdings Inc. (CRWE) at www.crownequityholdings.com
**
The price of BIND Therapeutics, Inc. (BIND) stock surged in extended-hours trading Thursday after the company announced an extension of the terms of its global collaboration with pharmaceutical giant Pfizer Inc. (PFE) to create Accurins that optimize the therapeutic potential of two molecularly targeted oncology drugs in Pfizer's pipeline.
The timeline for Pfizer to exercise its option to acquire the exclusive license for the first program continues to be September 2015. BIND and Pfizer agreed to an extension of the timeline for the second program through March 2016.
Both companies mutually agreed to extend the research terms for the second of the two selected compounds in order to ensure it is fully evaluated and well-positioned to enter IND-enabling studies
BIND received an upfront payment of $4.0 million in 2013, a $1.0 million preclinical development milestone in December 2014, and has the potential to receive payments up to $88.5 million upon the achievement of additional specified development and regulatory events. BIND may also receive additional payments up to $110 million for specified commercial events as well as royalties in the low single to high single digit percentages on potential future sales of each Accurin commercialized, if any.
BIND's Accurins are polymeric nanoparticles that incorporate a therapeutic payload and are designed to have prolonged circulation within the bloodstream, enable targeting of the diseased tissue or cells, and provide for the controlled and timely release of the therapeutic payload
Shares of BIND surged $0.13 (or +2.41%) to $5.52 in the last trading session
BIND is a clinical-stage nanomedicine platform company developing a pipeline of Accurins, its novel targeted therapeutics designed to increase the concentration and duration of therapeutic payloads at disease sites while reducing exposure to healthy tissue. BIND has demonstrated in preclinical studies that Accurins can improve tumor growth suppression, achieve higher concentrations of the payload in tumors compared to the payload administered in conventional form, and have pharmacokinetics and tolerability differentiated from their therapeutic payloads.
More about BIND Therapeutics, Inc. (BIND) at www.bindtherapeutics.com
**
Disclaimer: DrStockPick.com is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read Full Disclaimer at www.DrStockPick.com/disclaimer
CRWE Network's business model is based on selling advertising to businesses targeting both locally and nationally
The CRWE Network has reached the 1487th community website in the U.S. and includes coverage in the states of California, Mississippi, Michigan, Florida, Nevada and New York, as well as across 10 provinces in Canada.
The CRWE-PR Business Directory portal ( www.BusinessDirectory.crwe-pr.com ) is the company’s business directory service that is available to all United States and Canada business in the public and private sector. It allows business owners and executives the ability to claim their business listings and provide more detailed information for their potential customers who visit the CRWE Network everyday.
The CRWE-PR Finance website ( www.finance.crwe-pr.com ) allows Crown Equity Holdings the instant distribution of breaking business and financial news to the entire CRWE Network
The company’s CRWE Press Release ( www.crwepressrelease.com ) offers increased visibility with cost effective solutions through the distribution of information to the entire CRWE Network for both public and private companies.
Crown Equity Holdings’ CRWE Real Estate ( www.CRWERealEstate.com ) is expected to be integrated in all the CRWE Network. It will allow people to submit their listings for exposure to visitors searching for homes.
Online video is gaining strength as a source for content marketing. Strategic plans are being developed for the company’s division CRWE Tube ( www.crwetube.com ), expected to be integrated in all the CRWE Network
The Medical Marijuana CRWE-PR website ( www.medicalmarijuana.crwe-pr.com ) is a news and information database of medical marijuana doctors, dispensaries, deliveries and lawyers across the nation.
CRWE‘s subsidiary EQCO2, Inc. (CLNO) is in the process of changing its name for iB2B Global and its direction of operations to that of a business to business (B2B) international e-commerce company with an online and mobile optimized platform to facilitate e-commerce between manufacturers and buyers.
CRWE‘s iB2B Global ( www.iB2BGlobal.com ) was created to bring business communities from similar and different continents together online, enabling a cost effective access point for bulk products to be bought, sold and shipped in a timely manner.
CRWE has signed a Letter of Intent (LOI) to acquire 95% stake in American Video Teleconferencing Corp. (AVOT), which has two (2) sub-company operations known as, Roxzu and AVOTube.
Roxzu ( www.roxzu.com ) in development stage, is an on-line e-commerce coupon distribution channel and marketplace for merchants to create brand awareness for their business. The geo-location based mobile marketing application Roxzu is expected to be integrated in all the CRWE Network.
AVOTube ( www.avotube.com ) is a video-sharing hosting service that allows user to upload videos to share for exposure, branding, marketing and advertising.
CRWE provides marketing solutions that boost customer awareness and merchant visibility on the Internet.
More about Crown Equity Holdings Inc. (CRWE) at www.crownequityholdings.com
**
The price of BIND Therapeutics, Inc. (BIND) stock surged in extended-hours trading Thursday after the company announced an extension of the terms of its global collaboration with pharmaceutical giant Pfizer Inc. (PFE) to create Accurins that optimize the therapeutic potential of two molecularly targeted oncology drugs in Pfizer's pipeline.
The timeline for Pfizer to exercise its option to acquire the exclusive license for the first program continues to be September 2015. BIND and Pfizer agreed to an extension of the timeline for the second program through March 2016.
Both companies mutually agreed to extend the research terms for the second of the two selected compounds in order to ensure it is fully evaluated and well-positioned to enter IND-enabling studies
BIND received an upfront payment of $4.0 million in 2013, a $1.0 million preclinical development milestone in December 2014, and has the potential to receive payments up to $88.5 million upon the achievement of additional specified development and regulatory events. BIND may also receive additional payments up to $110 million for specified commercial events as well as royalties in the low single to high single digit percentages on potential future sales of each Accurin commercialized, if any.
BIND's Accurins are polymeric nanoparticles that incorporate a therapeutic payload and are designed to have prolonged circulation within the bloodstream, enable targeting of the diseased tissue or cells, and provide for the controlled and timely release of the therapeutic payload
Shares of BIND surged $0.13 (or +2.41%) to $5.52 in the last trading session
BIND is a clinical-stage nanomedicine platform company developing a pipeline of Accurins, its novel targeted therapeutics designed to increase the concentration and duration of therapeutic payloads at disease sites while reducing exposure to healthy tissue. BIND has demonstrated in preclinical studies that Accurins can improve tumor growth suppression, achieve higher concentrations of the payload in tumors compared to the payload administered in conventional form, and have pharmacokinetics and tolerability differentiated from their therapeutic payloads.
More about BIND Therapeutics, Inc. (BIND) at www.bindtherapeutics.com
**
Disclaimer: DrStockPick.com is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read Full Disclaimer at www.DrStockPick.com/disclaimer
(0)
(0)Pfizer Inc. (PFE) Stock Research Links
Scroll down for more posts ▼